NCT03362619

Brief Summary

The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
54mo left

Started Jun 2026

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Jun 2026Dec 2030

First Submitted

Initial submission to the registry

November 20, 2017

Completed
15 days until next milestone

First Posted

Study publicly available on registry

December 5, 2017

Completed
8.5 years until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2030

Last Updated

June 23, 2026

Status Verified

May 1, 2026

Enrollment Period

3.6 years

First QC Date

November 20, 2017

Last Update Submit

June 18, 2026

Conditions

Cervical Cancer

Keywords

Cervical cancerCytotoxic lymphocyteCC-CTL

Outcome Measures

Primary Outcomes (1)

  • Safety of CC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events

    Physiological parameter (measuring cytokine response, fever, symptoms)

    6 months

Secondary Outcomes (2)

  • Functional analyses of CC-EIEs in vitro

    4 weeks

  • Anti-tumor effects

    1 year

Study Arms (1)

CC-EIEs

EXPERIMENTAL

Autologous cervical cancer specific engineered immune effectors (EIEs)

Biological: CC-EIEs

Interventions

CC-EIEsBIOLOGICAL

2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time

CC-EIEs

Eligibility Criteria

Age10 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Written, informed consent obtained prior to any study-specific procedures.
  • Age older than 10 years.
  • Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
  • Expected survival ≥ 12 weeks.
  • Not pregnant, and on appropriate birth control if of childbearing potential.
  • Evidence of high-risk HPV infection.
  • Stage III-IV or recurrent cervical cancer.
  • Initial hematopoietic reconstitution with
  • neutrophils (ANC) ≥ 1,000/mm\^3;
  • platelet (PLT) ≥ 100,000/mm\^3.
  • Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with
  • serum creatinine ≤ 2×ULN;
  • serum bilirubin ≤ 2×ULN;
  • AST/ALT ≤ 2×ULN;
  • ALKP ≤ 5×ULN;
  • +2 more criteria

You may not qualify if:

  • Patients with
  • cervical benign lesions: cervical columnar epithelium ectopic, cervical polyps, cervical endometriosis and cervical tuberculous ulcers;
  • cervical benign tumors: cervical submucous myoma, cervical cancer, cervical papilloma.
  • Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure (prior, current or planned treatment).
  • Previous exposure to mouse SCC antibody.
  • Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study.
  • Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).
  • Pregnant or lactating females.
  • Inadequate bone marrow function with
  • absolute neutrophil count \< 1,000/mm\^3;
  • platelet count \< 100,000/mm\^3;
  • Hb \< 9 g/dL.
  • Inadequate liver and renal function with
  • serum (total) bilirubin \> 1.5 x ULN;
  • AST \& ALT \> 2.5 x ULN (\> 5 x ULN in patients with liver metastases);
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, 518000, China

RECRUITING

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Lung-Ji Chang, PhD

    Shenzhen Geno-Immune Medical Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lung-Ji Chang, PhD

CONTACT

+86 0755-86573763c@szgimi.org

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
President

Study Record Dates

First Submitted

November 20, 2017

First Posted

December 5, 2017

Study Start

June 1, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2030

Last Updated

June 23, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)